1,471 reports of this reaction
4.2% of all VALBENAZINE reports
#5 most reported adverse reaction
TARDIVE DYSKINESIA is the #5 most commonly reported adverse reaction for VALBENAZINE, manufactured by Neurocrine Biosciences, Inc.. There are 1,471 FDA adverse event reports linking VALBENAZINE to TARDIVE DYSKINESIA. This represents approximately 4.2% of all 34,810 adverse event reports for this drug.
Patients taking VALBENAZINE who experience tardive dyskinesia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
TARDIVE DYSKINESIA is moderately reported among VALBENAZINE users, representing a notable but not dominant share of adverse events.
In addition to tardive dyskinesia, the following adverse reactions have been reported for VALBENAZINE:
The following drugs have also been linked to tardive dyskinesia in FDA adverse event reports:
TARDIVE DYSKINESIA has been reported as an adverse event in 1,471 FDA reports for VALBENAZINE. This does not prove causation, but indicates an association observed in post-market surveillance data.
TARDIVE DYSKINESIA accounts for approximately 4.2% of all adverse event reports for VALBENAZINE, making it a notable side effect.
If you experience tardive dyskinesia while taking VALBENAZINE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.